ProfileGDS5678 / 1440514_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 35% 35% 36% 34% 35% 37% 37% 35% 40% 36% 35% 34% 35% 35% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.8269835
GSM967853U87-EV human glioblastoma xenograft - Control 22.7992435
GSM967854U87-EV human glioblastoma xenograft - Control 32.8115836
GSM967855U87-EV human glioblastoma xenograft - Control 42.7130634
GSM967856U87-EV human glioblastoma xenograft - Control 52.7594635
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.9186137
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.9003637
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.7870735
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.8993440
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.800436
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.7856935
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.7424134
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.805735
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.7905135